eel ventricular natriuretic peptide

from eel cardiac ventricles, exhibits the entire spectrum of actions known to be characteristic of atrial & brain natriuretic peptides; not found in mammals; amino acid sequence given in first source

Also Known As:

Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yu, Jun: 6 articles (02/2015 - 02/2002)
2.	Zhu, Miao-Zhang: 5 articles (09/2010 - 02/2002)
3.	Tie, Ru: 3 articles (02/2015 - 01/2010)
4.	Chen, Bao-Ying: 3 articles (11/2013 - 01/2010)
5.	Lu, Shun-Yan: 3 articles (05/2005 - 02/2002)
6.	Zhu, Xiao-Xing: 2 articles (09/2010 - 01/2010)
7.	Qu, Ping: 2 articles (09/2010 - 01/2010)
8.	Xing, Wenjuan: 1 article (02/2015)
9.	Zhang, Haifeng: 1 article (02/2015)
10.	Ji, Lele: 1 article (02/2015)

Related Diseases

1.	Anoxia (Hypoxia) 02/01/2003 - "[Study on the mechanism of how vasonatrin peptide can attenuate the growth-promoting effect of hypoxia in cardiac fibroblasts]." 02/01/2003 - "To investigate how vasonatrin peptide (VNP) can attenuate the growth-promoting effect of hypoxia in cardiac fibroblasts cultured from neonatal rats. " 02/25/2002 - "The present work was to investigate the effects of vasonatrin peptide (VNP) on cardiomyocyte protein synthesis induced by moderate hypoxia. " 02/25/2002 - "[Inhibition of moderate hypoxia-induced protein synthesis by vasonatrin peptide in cultured neonatal rat cardiomyocytes]." 08/01/2001 - "The purpose of this work was to test the hypothesis that vasonatrin peptide (VNP) can attenuate the growth-promoting effect by hypoxia in cardiac fibroblasts of cultured neonatal rats. "
2.	Pulmonary Hypertension (Ayerza Syndrome) 01/01/2010 - "Protective effects of vasonatrin peptide against hypobaric hypoxia-induced pulmonary hypertension in rats." 01/01/2010 - "1. The aim of the present study was to investigate the in vivo effects of vasonatrin peptide (VNP) on hypoxia-induced pulmonary hypertension (HPH). "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 02/15/2015 - "Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms." 02/15/2015 - "Although atrial natriuretic peptide and C-type natriuretic peptide reduce the myocardial ischemia-reperfusion damage in nondiabetic rats, whether vasonatrin peptide (VNP), the artificial synthetic chimera of atrial natriuretic peptide and C-type natriuretic peptide, confers cardioprotective effects against ischemia-reperfusion injury, especially in diabetic patients, is still unclear. "
4.	Reperfusion Injury 02/15/2015 - "Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms." 02/15/2015 - "Although atrial natriuretic peptide and C-type natriuretic peptide reduce the myocardial ischemia-reperfusion damage in nondiabetic rats, whether vasonatrin peptide (VNP), the artificial synthetic chimera of atrial natriuretic peptide and C-type natriuretic peptide, confers cardioprotective effects against ischemia-reperfusion injury, especially in diabetic patients, is still unclear. "
5.	Wounds and Injuries (Trauma) 11/01/2013 - "Vasonatrin peptide, a novel protector of dopaminergic neurons against the injuries induced by n-methyl-4-phenylpyridiniums."

Related Drugs and Biologics

1.	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)
2.	Collagen
3.	Carbon Tetrachloride (Tetrachloromethane)